|
AVLN Avalyn Pharma Inc 1540171 |
| Income Statement |
|
Net Income
|
2026-03-31
|
$-26,869,000.00 |
| Balance Sheet |
|
Current Assets
|
$129,987,000.00 |
|
Assets
|
$135,663,000.00 |
|
Current Liabilities
|
$11,787,000.00 |
|
Liabilities
|
$27,687,000.00 |
|
Equity
|
$-264,245,000.00 |
|
Shares Out
|
1232442.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-29,891,000.00 |
|
Investing Cash Flow
|
$55,024,000.00 |
| Market Analysis |
Market Cap
|
$36,122,875.02 |
|
Price
|
$27.78 |
|
PB
|
2.55 |
|
EPS
|
-21.83 |
|
FCF
|
$-30,209,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-08-01 09:31:24 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-08-03 10:01:20 |
|
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view AVLN documents filed with the SEC.
AVLN Filings
Clear
